NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: OYE Therapeutics' $5.475M Series A Funding for High-Concentration Caffeine Therapy
TL;DR
OYE Therapeutics' $5.475M Series A funding provides a competitive edge in developing high-concentration caffeine therapy for anesthesia recovery and opioid emergencies.
OYE Therapeutics plans a Phase 1 trial in Q1 2026 for intravenous caffeine therapy that works alongside naloxone to support respiratory drive during opioid recovery.
This therapy could make tomorrow better by improving patient recovery from anesthesia and potentially saving lives during opioid-induced respiratory emergencies.
OYE Therapeutics' name stands for 'Open Your Eyes,' reflecting their vision to solve clinical problems others have accepted as intractable.
Found this article helpful?
Share it with your network and spread the knowledge!
OYE Therapeutics is a clinical-stage pharmaceutical company developing a caffeine platform for anesthesia recovery and opioid-induced respiratory depression (OIRD). The company focuses on transforming overlooked clinical problems into solvable challenges through breakthrough enhancements.
OYE Therapeutics raised $5.475 million in a Series A financing on November 28, 2025. The financing was oversubscribed, meaning it exceeded the initial target amount.
OYE Therapeutics' proprietary product is a high-concentration intravenous caffeine therapy designed for anesthesia recovery and opioid-induced respiratory depression (OIRD). It aims to accelerate recovery from anesthesia and address fentanyl-related intoxication.
The company expects to begin a Phase 1 clinical trial in Q1 2026 (first quarter of 2026).
The investigational therapy is designed to be used alongside naloxone, aiming to support wakefulness and respiratory drive during recovery from opioid-induced respiratory depression. It works through a novel mechanism distinct from naloxone.
The company is pursuing a broad platform including military/civilian acute care applications. The therapy is designed to address opioid-induced respiratory depression, particularly relevant for fentanyl-related intoxication.
WBB Securities LLC acted as the placement agent for this transaction. WBB Securities is an investment management, investment banking, and equity research firm focused on life sciences.
OYE stands for 'Open Your Eyes,' which reflects both the clinical necessity of waking patients and the company's metaphorical vision of rethinking problems others have resigned to live with.
OYE Therapeutics is based in Crown Point, Indiana. Key contacts include Brett Dines (bdines@oyetherapeutics.com) from OYE Therapeutics and Steve Brozak (sbrozak@wbbsec.com) from WBB Securities.
You can view the full announcement, including downloadable images and bios, by clicking here. The source is OYE Therapeutics, distributed by Reportable, Inc.
Curated from Reportable
